“Still we're committed to high single-digit growth and double-digit EPS growth.”

In context

“, which we now expect to be just $200 million of impact. FX, as Phil kind of said in his comments, is still a headwind versus prior year on the EPS side, but much less of a headwind than what we originally kind of anticipated back in January and quite frankly [ people], too. So that helps offset some of the tariff impact. So I put this all together, and you got -- it will be nice, David, to lap these to see these headwinds behind us next year. And then as you look to next year, you got all this great launch activity across all the businesses, whether it's Vault in the U.S., [ TACTIFLexDuo ] internationally, the dual analyte sensor, the launch of the new Alinity system the biosimilar kind of rollout. So I look at all of that and I say, okay, you've got this headwind that we're facing here. Still we're committed to high single-digit growth and double-digit EPS growth. And then as you look into 2026, those headwinds aren't going to be there. And then you've got all this kind of great momentum, which I'm sure we'll talk about in other parts of the business. So I look at 2026, I look at -- I know what the consensus are. They look very reasonable to me in that range of high single digits, double-digit EPS. It's in line with our historical growth. It's in line with the guidance we've given this year, and it's in line with what our long-term sustainable growth targets are. So yes, it will be good to see these elements here that I've just kind of highlighted that are specifically to diagnostics. And I'll just take it a step further here. I mean if you look at our -- and I mentioned this in the opening comments here, our core lab business outside, and I hate d”